APA

Labidi-Galy S. I., Clauss A., Ng V., Duraisamy S., Elias K. M., Piao H., Bilal E., Davidowitz R. A., Lu Y., Badalian-Very G., Györffy B., Kang U., Ficarro S., Ganesan S., Mills G. B., Marto J. A. & Drapkin R. (20150422). Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. : Oncogene.

Chicago

Labidi-Galy S I, Clauss A, Ng V, Duraisamy S, Elias K M, Piao H-Y, Bilal E, Davidowitz R A, Lu Y, Badalian-Very G, Györffy B, Kang U-B, Ficarro S, Ganesan S, Mills G B, Marto J A and Drapkin R. 20150422. Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. : Oncogene.

Harvard

Labidi-Galy S. I., Clauss A., Ng V., Duraisamy S., Elias K. M., Piao H., Bilal E., Davidowitz R. A., Lu Y., Badalian-Very G., Györffy B., Kang U., Ficarro S., Ganesan S., Mills G. B., Marto J. A. and Drapkin R. (20150422). Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. : Oncogene.

MLA

Labidi-Galy S I, Clauss A, Ng V, Duraisamy S, Elias K M, Piao H-Y, Bilal E, Davidowitz R A, Lu Y, Badalian-Very G, Györffy B, Kang U-B, Ficarro S, Ganesan S, Mills G B, Marto J A and Drapkin R. Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. : Oncogene. 20150422.